共 2 条
- [1] Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a "classical" strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an "optimized" strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
- [2] PHASE III, RANDOMIZED, MULTICENTER STUDY COMPARING IN ELDERLY PATIENTS (≥70 YEARS) WITH STAGE IV NON SMALL-CELL LUNG CANCER (NSCLC) A STANDARD STRATEGY OF TREATMENT ALLOCATION (CARBOPLATIN BASED BI-THERAPY OR MONOTHERAPY WITH DOCETAXEL) BASED ON PERFORMANCE STATUS (PS) AND AGE WITH AN EXPERIMENTAL STRATEGY ALLOCATING THE SAME CHEMOTHERAPIES OR BEST SUPPORTIVE CARE (BSC) ACCORDING TO A COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) - STUDY ESOGIA-GFPC-GECP 08-02 JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S192 - S193